The list celebrates individuals who are under 30 years of age who have made a significant impact in their field.
Mohanad has received the recognition for his work developing an AI digital twin called HyTwin, which can assess patients with hypertension using a holistic multi-organ multi-modality analysis.
HyTwin is an artificial digital twin of a patient which could be used by doctors to test how patients might react to certain management strategies, before applying them directly to the patient. The tool also provides clinicians, or patients at home, the ability to understand what impact their blood pressure is having on their organs, such as their heart and brain - going beyond simply focusing on their blood pressure numbers. How their blood pressure is affecting their body over time can then be tracked to see whether they are getting benefits from medications or lifestyle changes.
Mohanad, who is based in the Leeson Group, is working towards launching HyTwin as a startup with his team at CCRF. ‘I am deeply honoured to have my current DPhil work at Oxford recognized by Forbes. This recognition reflects not only the high-quality research we undertake at CCRF but also the invaluable skills we acquire as students in developing innovative solutions to medical challenges. I am profoundly grateful for the unwavering support and guidance of Prof. Paul Leeson and the exceptional team at CCRF,’ said Mohanad.
‘Our project, HyTwin, is being developed as an artificial partner for clinicians in clinical settings. It leverages cutting-edge machine learning tools to simulate patient scenarios, predict future outcomes, and generate a risk score for hypertension, helping to map patients onto specific progression trajectories.’
Professor Paul Leeson, Head of CCRF added: ‘Driving innovations within clinical practice is always a team effort and this project has been a great way to bring together biomedical engineers, doctors, specialist nurses and patients to address a health problem. The award from Forbes reflects the fundamental role Mohanad has had in developing the models underlying HyTwin and, excitingly, has recognised the disruptive potential of this tool for tackling hypertension - one of the biggest "silent killers" globally.’
In 2023, Mohanad was also selected among the MIT Technology Review Magazine Innovators Under 35 in the Middle East for the same tool.